AZNS Stock Overview
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
AstraZeneca PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1,654.25 |
| 52 Week High | UK£1,671.00 |
| 52 Week Low | UK£1,275.00 |
| Beta | 0.16 |
| 1 Month Change | 10.74% |
| 3 Month Change | 27.47% |
| 1 Year Change | 4.39% |
| 3 Year Change | 75.37% |
| 5 Year Change | 126.30% |
| Change since IPO | 459.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| AZNS | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -1.0% | -1.9% | 0.5% |
| 1Y | 4.4% | 6.4% | 6.3% |
Return vs Industry: AZNS underperformed the UK Pharmaceuticals industry which returned 6.4% over the past year.
Return vs Market: AZNS underperformed the UK Market which returned 6.3% over the past year.
Price Volatility
| AZNS volatility | |
|---|---|
| AZNS Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: AZNS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine AZNS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 89,900 | Pascal Soriot | www.astrazeneca.com |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease.
AstraZeneca PLC Fundamentals Summary
| AZNS fundamental statistics | |
|---|---|
| Market cap | kr2.55t |
| Earnings (TTM) | kr67.69b |
| Revenue (TTM) | kr509.05b |
37.6x
P/E Ratio5.0x
P/S RatioIs AZNS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AZNS income statement (TTM) | |
|---|---|
| Revenue | US$47.61b |
| Cost of Revenue | US$8.33b |
| Gross Profit | US$39.28b |
| Other Expenses | US$32.95b |
| Earnings | US$6.33b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 25, 2024
| Earnings per share (EPS) | 4.08 |
| Gross Margin | 82.50% |
| Net Profit Margin | 13.30% |
| Debt/Equity Ratio | 89.2% |
How did AZNS perform over the long term?
See historical performance and comparison